Peer Review History
| Original SubmissionJuly 18, 2020 |
|---|
|
PONE-D-20-22300 Competitive exclusion during co-infection as a strategy to prevent the spread of a virus: a computational perspective PLOS ONE Dear Dr. Sadeghi, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Nov 07 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Bashar Ibrahim Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: N/A Reviewer #3: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 5. Review Comments to the Author Reviewer #1: Dear authors, please notice the following comments and suggestions regarding your paper and correct the regarding parts if necessary: (1) lines 101 - 103: Is there a word missing? (2) caption of Fig. 2: "The each trajectory..." This sentence does not make sense. It appears several times in the paper !!! (3) !!! Almost all references to the Figure numbers in the text seem to be wrong, i.e. shifted by one !!! (4) line 178: "strong With limited capacity" - "w" is missing (5) lines 224 - 226: The plot does not really look LINEAR. How do you draw this conclusion. It could also be a quadratic or exponential decline. Reviewer #2: This study tries to assess the feasibility of use of co-infecting virus to combat problematic virus, based on simulation results. The main conclusion obtained by the authors is that if co-infecting (harmless) virus can accumulate more rapidly than the target (harmful) virus and if the two viruses compete for the same type of host cells, the target virus will be dominated by the co-infecting virus, even when the co-infecting virus came later; to be honest, this conclusion will not surprise anyone, but I can find a potential value of this study in establishment of a framework for discussion on “under what circumstances such antiviral strategy can function.” To fulfill the potential value of the study, I recommend the authors to consider the following points: Major points: 1) The simulation results are totally dependent on parameter values, especially on lambda. Please provide lambda (and other parameter) values used for the simulations explicitly in every figure; to avoid confusion, clearly define parameters. For example, define different lambda value for each virus by using lambda B and lambda M. 2) Please provide average waiting times for each step, as readers can compare them with D. 3) Figures and figure legends do not correspond to each other in some instances. I need explanation for Fig. 3 but I wonder where I can find it... 4) In Fig. 6, B virus continues to accumulate but M virus does not. Could the authors provide intuitive explanation of this phenomenon? For example, limitation in the number of host cells will not explain because B virus would also suffer. 5) In relation to the above comment, I’m not sure if the authors assumed (1) limitation in the number of cells, (2) host cell division, and (3) innate immunity in each figure. 6) In my understanding, authors think that competition for host cells is important in the simulation. Could the authors provide the time-course change of the number (and/or proportion) of cells attacked by both of the virus (before they get infected)? I’m not sure if the local spread of viruses assumed in this manuscript allows competition for host cells, though it totally depends on the virus and host cell densities assumed. 7) L40 and L312: the authors touch incubation times of viruses but it was not clear to me how they are relevant to this study. Other minor points: 8) Figure 2 Legend: Replication -> replication 9) L178: ith -> with 10) The reference formatting is terrible. Reviewer #3: In this paper the authors have presented an interesting framework for the progression of viral infection in host tissue. The model simulates the invasion of two competing viruses in a theoretical lattice of initially susceptible cells. Cells that are infected by one virus are prevented by being simultaneously infected by a competing strain to simulate the effect of the competitive exclusion principle (CEP). The premise of this paper therefore may be appealing to not only mathematical modellers but also biologists and medics working in related fields. However, I do have some key concerns, that if addressed would benefit the manuscript: - The authors do not provide a strong justification for the application of their model to SARS-CoV-2 in their introduction, which detracts from the narrative since the reader is left questioning the relevance of the model in this setting. Some justification is provided later in the discussion section, however, this is not particularly strong, and thus the application of the model to SARS-CoV-2 feels very extrapolative. I would therefore encourage the authors to consider removing the emphasis of the model’s application to SARS-CoV-2 in the abstract and introduction of the paper. - The action of the CEP in the model was buried in the paper (it was briefly alluded to in lines 201 -203). This could have been made much clearer. Moreover, it appears that the authors are more specifically modelling superinfection exclusion, whereby secondary infection is prevented at a cellular level, which I would consider to be a specific example of the CEP. - The paper would benefit if the model was described in clearer detail. For example, the authors have not made the action of the immune response in the model clear. I appreciate that to appeal to a wider audience that the authors may not wish to go into a great level of detail in the main body of the text, but I feel a more detailed description of all of the components of the model in the supplementary information would be very beneficial. - The paper would benefit from a more thorough justification of the parameterisation of the model, with suitable references to existing literature. While I appreciate different parameter combinations have been explored, this is somewhat limited, and I feel a more detailed sensitivity analysis would be beneficial. This also would most likely be appropriate to include in the supplementary information. - The authors do not appear to use time units in their parametrisation of the model, or in the results presented, where all figures are presented in “steps” along the x-axis. - The above point raises significant concerns – since the model is based on a Gillespie algorithm, each time step will be of a different time length due to different sojourn times between events. It could therefore be misleading to plot the trajectories of their results (e.g. number of virions) against the step count for each run of the simulation, since these are evolving over different timescales. I would therefore strongly advice that the model is revisited to ensure that all x-axes are presented over some units of time (hours or days). - Additionally, a thorough spelling and grammar check is required While I do have a significant number of concerns with the manuscript in its current form, I do believe that a valuable piece of work could result from the model framework that the authors have used. Moreover, I felt the premise of the model is interesting in principle and would like to thank the authors for sharing their work. I have made some additional inline comments below: line 69 - 70: If there is evidence of a reduced risk of a subsequent coronavirus infection by another respiratory virus then I think this needs to be explicitly stated to be able to back up the paper's justification for applying the model to SARS-CoV-2. Currently, it's not specified which pairs of viruses had a negative interaction between them in ref [10]. Line 133: The legend for figure 2 does not appear to match figure 2 in this document, which appears to show the different spreading patterns (square vs cross) line 165: Does "the capacity of the immune system (I)" have any units, such as the maximum number of infected cells/virions eliminated per day? It is not clear how "I" is defined mathematically in the model. line 167: Gamma appears to have been defined in lines 163-164 as "the rate at which the immune (system) eliminates infected cells or virions". Therefore, it presumably has units of "cells/virions cleared per hour/day". I therefore do not understand the logic behind why it is then drawn from a U[0,1] distribution. Line 176: to differentiate this from the "unlimited immune response capacity" situation, I think it would be better to have notation along the lines of 0>i<i_c bound.="" i_c="" is="" some="" upper="" where=""> line 199: It is unclear how the second virus is seeded into the model. It would be helpful if the authors clarified this (e.g. is it seeded into a cell in the lattice at random?) line 213: There is a lack of justification for the parameters chosen for the various distributions in table 1. While there may be limited literature for SARS-CoV-2, literature on other respiratory viruses may allow the authors to justify their choices. As highlighted before, I feel the paper would benefit if all times are given in appropriate units such as days, rather than being treated as dimensionless. I would also encourage the authors to consider including a sensitivity analysis of the different parameters in the supplementary information. lines 267-271: Hepatitis G is now typically referred to as GB virus C lines 312-314: If the authors wish to keep the focus of the paper on SARS-CoV-2, I feel the manuscript would benefit if these studies (refs [30] and [31]) were highlighted in the introduction section. The reader would then understand the authors justification for the model to be placed in the context of SARS-CoV-2.>/i<i_c> ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: Yes: Andrew C Glover [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-22300R1 Competitive exclusion during co-infection as a strategy to prevent the spread of a virus: a computational perspective PLOS ONE Dear Dr. Sadeghi, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jan 23 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Bashar Ibrahim Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #3: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #3: N/A ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The corrections regarding my revision were done well. I would agree to the publication of the paper now. Reviewer #3: I would like to thank the reviewers for addressing the comments myself and the other reviewers had made in response to the manuscript's initial submission, and believe the presentation of the work has improved as a result. I do nevertheless have some ongoing concerns: 1) While I am thankful that the authors have given an improved explanation behind their choice of parameters in the supplementary information, I still believe that the paper would benefit significantly if these were placed in the context of some real world viruses. Currently the choice of parameters, both in the main body of the text and the supplementary information, are entirely theoretical and have not been justified. I feel this would be acceptable if the paper was presented as a wholly theoretical piece of work, however, the authors ultimately conclude that "Co-Wish suggests that common respiratory viral infections - such as common human coronaviruses - may limit the replication of SARS-CoV-2" (lines 317-318). Yet, when the choice of parameters is entirely theoretical, I do not believe such conclusions should be drawn, or even alluded to. 2) The results of the paper are still presented over steps rather than units of time. While I appreciate the authors responded to this point when I raised it previously, I still feel that it would be important to translate the results to be presented over time units if conclusions such as the one highlighted above are to be drawn. Moreover, it should not be too difficult for the authors to record the sojourn times between events from a Gillespie algorithm. While I still have these concerns, I do hope that the authors are not too disheartened and want to stress that I still believe it is an interesting piece of work. I do however believe that the authors should consider taking one of either of the following approaches: - Revisiting their model to present their results in units of time, with a choice of parameters that have been justified in some way from common respiratory viruses. I appreciate that there will be a lot of unknowns for the waiting times between different stages for real world viruses, but I believe it would be possible to make at least sensible ballpark estimates. If this were to be done, then I feel the authors would have more justification to make conclusions that could be placed in a real world context. - However, if the authors do not wish to re-run their model and results, as suggested above, I feel the narrative of the paper should be revisited to emphasize that it is an entirely theoretical piece of work, and that any conclusions in relation to any real world viruses should not be made or alluded to. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #3: Yes: Andrew Glover [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
PONE-D-20-22300R2 Competitive exclusion during co-infection as a strategy to prevent the spread of a virus: a computational perspective PLOS ONE Dear Dr. Sadeghi, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a minor revised version of the manuscript that addresses the points raised during the review process. "Please elaborate more about the difference between your approach and other literature theoretical approaches particularly there is a huge number recent models and also software tools for SARS-CoV-2 and some on a related study. This would help and guide readers more in the introduction or discussion. I listed a few examples and more is even better in this case: 10.20944/preprints202005.0376.v1 10.1155/2020/4923856 10.1007/s00018-019-03382-0 https://doi.org/10.1016/j.bihy.2008.05.003 10.3390/v13010014 " Please submit your revised manuscript by Feb 27 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Bashar Ibrahim Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 3 |
|
Competitive exclusion during co-infection as a strategy to prevent the spread of a virus: a computational perspective PONE-D-20-22300R3 Dear Dr. Sadeghi, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Bashar Ibrahim Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-20-22300R3 Competitive exclusion during co-infection as a strategy to prevent the spread of a virus: a computational perspective Dear Dr. Sadeghi: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Bashar Ibrahim Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .